Star Alliance, the world’s first and largest global airline alliance, is pleased to announce that Theo Panagiotoulias has been chosen to become its next CEO. Mr Panagiotoulias has more than 25 years’ international experience in the airline and aviation industry. He joins Star Alliance from Hawaiian Airlines, where he had been Senior VP for Global Sales and Alliances since 2014. Previously, Mr Panagiotoulias was VP and GM (Asia Pacific) at travel technology provider Sabre Corporation, as well as a 15year veteran of American Airlines, where he held several commercial, operational and management positions. His full biography is appended. “On behalf of the board of Star Alliance, I would like to congratulate Theo for being named the next CEO of Star Alliance,” said Scott Kirby, CEO of United Airlines and Chairman of the Star Alliance Chief Executive Board. “Theo’s international commercial and airline experience have given him a good understanding of the challenges and opportunities facing our industry today. I believe he is the right person to lead Star Alliance into the future.” “Star Alliance connects the world,” said Mr Panagiotoulias. “More than 200 million customers fly with its 26 member airlines each year, on more than 16,000 flights each day. The Alliance has also led the revolution to promote a more seamless passenger experience. I am honoured that I’ve been chosen to lead the Star Alliance team and work directly with our 26 member carriers, as we continue to innovate as the world’s leading airline alliance.” Mr Panagiotoulias will succeed Charlotta Wieland, who has been seconded from SAS – Scandinavian Airlines to serve as Star Alliance’s interim CEO since January 2023. With Mr Panagiotoulias coming on board, Ms Wieland will return to SAS, and also rejoin Star Alliance’s Alliance Management Board as the representative for SAS. Mr Panagiotoulias’ appointment is expected to take effect within the coming months, upon the completion of certain administrative processes and clearances. “On behalf of Star Alliance and its member carriers, I would like to thank Charlotta for her service to Star Alliance as interim CEO, and welcome her back to her seat on the Alliance Management Board,” said Mr Kirby. Star Alliance was named the World’s Best Airline Alliance by Skytrax in 2022. It aims to facilitate a seamless, high-quality traveller experience across its 26 member carriers, with smooth transfers across an extensive global network, together with rewards and recognition for frequent international travellers. In 2022, the Alliance celebrated its 25th anniversary as the longest-running international airline alliance. It also marked several important milestones, including the launch of the world’s first airline alliance credit card with HSBC Australia, and the formation of an intermodal travel model, which extends the Alliance’s network beyond air travel to other transport ecosystems, such as rail networks. Star Alliance names Theo Panagiotoulias as New CEO • Combines strong US business development track record with indepth mRNA expertise • Global remit with focus on growth of etherna’s portfolio of partners • Integrated offering key differentiator – Proprietary customized RNA chemistry and lipid nanoparticles (cLNPs) expertise combined with GMP process knowhow Etherna, a leading mRNA technologies company, announced today that Steffen Helmling, PhD has been appointed Chief Business Officer. He joins as the Company continues to invest in its proprietary RNA-based medicines and LNP delivery platforms to exploit its expertise in the field. Leveraging over 18 years of experience in business development, alliances and pharma partnering, Steffen will focus on growing etherna’s portfolio of partners globally. Steffen Helmling arrives from X-Chem, Inc., the Boston-based pioneer of DNA-Encoded Library (DEL) technology where he was Chief Business Officer in charge of business development, licensing, marketing and alliance management. Steffen holds a PhD in RNA processing from Tufts University’s School of Biomedical Sciences. Steffen commented: “I am excited to be back in the transformational field of RNA-based medicines. etherna is a highly innovative leader in the mRNA and lipid nanoparticle field. I look forward to driving our business strategy of being the premier discovery and development partner to pharma and biotech to create novel medicines for patients.” Bernard Sagaert, interim CEO of etherna, added: “Having Steffen on board will be invaluable in helping us reach out to partners with a route into mRNA therapeutics based on our industry-leading leading platforms. His extensive US network will help us accelerate this process in this key market.” Since etherna was founded in 2013, the Company has established an integrated set of proprietary capabilities for end-to-end design, development and manufacture of next-generation mRNA products, with a focus on modulated expression delivery platforms, optimized RNA chemistry supported by proprietary process techologies. These include molecular designs, lipid biochemistry expertise, customized lipid nanoparticle formulations (cLNPs), mRNA-based T cell adjuvants, and advanced manufacturing processes, and overcome the current challenges facing the development of mRNA therapeutics. etherna’s business model utilizes this suite of capabilities as enablers to deliver superior products for partners in both early-stage research as well as later-stage development for mRNA therapeutics.
RkJQdWJsaXNoZXIy MTQxNTg3MQ==